Sojo PJR, Vargas ÁAJ

Idioma: Español
Referencias bibliográficas: 15
Paginas:
Archivo PDF: 181.47 Kb.

RESUMEN

El uso de fármacos antineoplásicos aumenta el riesgo de enfermedad tromboembólica en pacientes oncológicos. Los primeros meses de tratamiento representan el mayor riesgo trombótico, y las comorbilidades medicas mayores y/o las complicaciones infecciosas también aumentan este riesgo. Combinar inmunomoduladores con dexametasona o quimioterapia citotóxica aumenta la incidencia de trombosis en el escenario de mieloma múltiple o linfoma no Hodgkin. El uso de sales de platino, fluropirimidinas y L-asparraginasa también se han identificado como factores de riesgo para enfermedad tromboembólica. Con relación a las terapias dirigidas, los inhibidores del receptor del factor de crecimiento epidermico se han asociado con aumento de eventos tromboembólicos. Por su parte los inhibidores del factor de crecimiento endotelial vascular, espeficamente los anticuerpos monoclonales, se han asociado con trombosis venosas y arteriales. Los corticoides en dosis altas aumentan la incidencia de tromboembolismos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers. 2020; 12:2535. Doi: https://doi.org/10.3390/cancers12092535

2. Debbie Jiang MD, Alfred Ian Lee MD. Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treat Res. 2019; 179:87-101. doi: https://doi.org/10.1007/978-3-030-20315-3_6

3. William D. Leslie, Suzanne N. Morin, Lisa M. Lix, Saroj Niraula, Eugene V. McCloskey, Helena Johansson, Nicholas C. Harvey, John A. Kanis, Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study. The Oncologist, Noviermbre 2019;24(11):1432–1438, https://doi.org/10.1634/theoncologist.2019-0149

4. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 10 de febrero de 2020;38(5):496- 520. Doi: https://doi.org/10.1200/JCO.19.01461

5. Carlos Bravo-Pérez, Vicente Vicente, Javier Corral, Management of antithrombin deficiency: an update for clinicians. Expert Review of Hematology 2019;12 (6): 397-405.https://doi.org/10.1080/17474086.2019.1611424

6. David K. Lau , Justin Mencel, Ian Chau, Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opinion on Drug Safety 2022; 21 (5): 589-597.https://doi.org/10.1080/14740338.2022.2008905

7. Francesca Bergamo, Sara Lonardi, Beatrice Salmaso, Carmelo Lacognata, Francesca Battaglin, Francesco Cavallin, Luca Saadeh, Sabina Murgioni, Antonino Caruso, Camillo Aliberti, Vittorina Zagonel, Carlo Castoro & Marco Scarpa. Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients, Acta Oncologica, Julio 2017; 57:3, 412- 419 https://doi.org/10.1080/0284186X.2017.1351038

8. Lidia Rita Corsini, Daniele Fanale, Francesco Passiglia, Lorena Incorvaia, Vincenzo Gennusa, Viviana Bazan & Antonio Russo. Monoclonal antibodies for the treatment of non-hematological tumors: a safety review, Expert Opinion on Drug Safety, Noviembre 2018; 17(12): 1197- 1209, https://doi.org/10.1080/14740338.2018.1550068

9. Chih-Chieh Yen, Chia-Jui Yen, Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha- fetoprotein. Expert Opinion on Drug Safety 2021; 21 (2): 157-166. Doi: https://doi.org/10.1080/14740338.2022.1995353

10. Celine Debeuckelaere, Sabina Murgioni, Sara Lonardi, Noemi Girardi, Giulia Alberti, Carolina Fano, Sara Gallimberti, Cristina Magro, Selma Ahcene-Djaballah, Francesca Daniel, Matteo Fassan, Hans Prenen & Fotios Loupakis. Ramucirumab: the long and winding road toward being an option for mCRC treatment, Expert Opinion on Biological Therapy, 2019; 19(5): 399-409, https://doi.org/10.1080/14712598.2019.1600505

11. Alba Noguerido, Núria Mulet-Margalef, Ignacio Matos, Javier Ros, Guillem Argilés, Elena Élez & Josep Tabernero. The safety of ramucirumab for the treatment of colorectal cancer, Expert Opinion on Drug Safety, 2018; 17(9): 945-951, doi: https://doi.org/10.1080/14740338.2018.1506762

12. Maria Vassilakopoulou, Kazuto Harada & Jaffer A Ajani (2018) Ramucirumab for the treatment of gastric adenocarcinoma, Expert Opinion on Orphan Drugs, 2018; 6:8, 449-455, doi: https://doi.org/10.1080/21678707.2018.1500689

13. Ana Marija Sola, Daniel E. Johnson & Jennifer R. Grandis. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms, Expert Opinion on Investigational Drugs, 2019; 28(4), 351-363, doi: https://doi.org/10.1080/13543784.2019.1581172

14. Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, et al. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Ann Hematol. febrero de 2019;98(2):331-337, doi: https://doi.org/10.1007/s00277-018-3509-0

15. Vasileios Papadopoulos, Konstantinos Tsapakidis, Alexandra Markou, Alexandros Kokkalis, Chrissovalantis Aidarinis & Athanasios Kotsakis. New prophylaxis strategies to reduce the risk of thromboembolism in cancer, Expert Review of Anticancer Therapy, 2021; 21(10), 1135- 1144, doi: https://doi.org/10.1080/14737140.2021.1941889